X
<

Closing In on Year End and Reviewing Pfizer as an Investment

PART:
1 2 3 4 5 6 7 8 9 10
Closing In on Year End and Reviewing Pfizer as an Investment PART 1 OF 10

Analyst Recommendations for Pfizer and Its Peers in 2016

Analyst recommendations

Based on the recommendations of 27 brokerage firms in a Bloomberg survey, 57.7% of analysts gave Pfizer (PFE) a “buy” recommendation while 42.3% analysts rated the company a “hold.” None of the analysts rated Pfizer a “sell.”

In 1H16, Pfizer reported strong financial performance that is buoyed by robust growth of its new products, as well as those products that are expected to lose patent exclusivity in the next few years. In addition to strong operational revenue growth in developed markets, the company also reported healthy performance in emerging markets. Among its core brands, Ibrance, Chantix, Lyrica, Xeljanz, and Eliquis drive Pfizer’s growth in 2016.

Analyst Recommendations for Pfizer and Its Peers in 2016

Interested in PFE? Don't miss the next report.

Receive e-mail alerts for new research on PFE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The consensus 12-month target price for Pfizer is ~$38.95, which represents a rise of 19.5% from the stock’s last price of $32.60 on October 19, 2016.

If Pfizer’s share price manages to surpass this price target, it may also boost the iShares Russell 1000 ETF (IWB). Pfizer makes up ~0.95% of IWB’s total portfolio.

Peer companies

Based on a Bloomberg survey of nine broker firms, Novartis (NVS) received “buy” recommendations from 62.5% of the firms and “hold” recommendations from 37.5% of the firms. The consensus 12-month target price for Novartis is ~$93.40, which represents a rise of 23.5% from the stock’s last price of $75.65 on October 19, 2016.

Among the 28 brokerage firms surveyed by Bloomberg for Eli Lilly (LLY), 80.8% gave it a “buy” recommendation while 19.2% gave it a “hold” recommendation. The consensus 12-month target price for Eli Lilly is ~$98.15, which represents a rise of 24.9% from the stock’s last price of $78.56 on October 19, 2016.

Based on the recommendations of 27 broker firms in a Bloomberg survey, Merck (MRK) received approximately equal “buy” and “hold” recommendations from the firms. The consensus 12-month target price for Merck is ~$67.75, which represents a rise of 9.5% from the stock’s closing price of $61.87 on October 19, 2016.

In the next article, we’ll explore growth trends for Pfizer’s Lyrica in 2016.

X

Please select a profession that best describes you: